Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

European Journal of Haematology

Volumn 84, Issue 4, 2010, Pages 332-336

  Ludek, Pour ^a,b   Hana, Svachova ^b   Zdenek, Adam ^a,b   Martina, Almasi ^b   Dana, Kralova ^b   Tomas, Buchler ^c   Lucie, Kovarova ^b   Marta, Krejci ^a   Jaroslav, Michalek ^b   Miroslav, Penka ^a   Jiri, Vorlicek ^a   Roman, Hajek ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Bortezomib; Chemokines; Multiple myeloma; Therapeutic response

Indexed keywords

BORTEZOMIB; SCATTER FACTOR; THROMBOSPONDIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW; BORONIC ACIDS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PYRAZINES; RECURRENCE; THROMBOSPONDINS;

EID: 77949479635     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01396.x     Document Type: Article

References (27)

1. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
2. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-6.
3. Neben K, Moehler T, Kraemer A, et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001;115:605-8.
4. Sezer O, Jakob C, Eucker J, et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in muliple myeloma. Eur J Haematol (Denmark) 2001;66:83-8.
5. Ščudla V, Budíková M., Pika T. et al. Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma. Vnitr Lek 2006;52:232-40. Czech.
6. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003;72:229-33.
7. Pour L, Svachova H, Adam Z, et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010;57:29-34.
8. Standal T, Abildgaard N, Fagerli U, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007;109:3024-30.
9. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
10. San Miguel JF, Schlag R, Khuageva NKet al.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
11. Papageorgiou A, Kamat A, Benedict WF, et al. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006;5:3032-41.
12. Roccaro AM, Hideshima T, Raje N. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-91.
13. Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008;22:2247-56. Epub 2008 Sep.
14. Politou M, Naresh K, Terpos E, et al. Anti-angiogenic effect of bortezomib in patients with multiple myeloma. Acta Haematol 2005;114:170-3.
15. Cibeira MT, Rozman M, Segarra M, et al. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 2008;41:244-53. Epub 2008 Jan 4.
16. Rajkumar SV, Yoon SY, Li CY, et al. Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells. Blood 1999;94:303b.
17. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006;20:193-9.
18. Urbanska-Rys J. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment. Mediators Inflamm 2003;12:229-35.
19. Dmoszynska A, Bojarska-Junak A, Domanski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma 2002;44:1347-51.
20. Pour L, Kovarova L, Buchler T, et al. Evaluation of hepatocyte growth factor and endostatin in the bone marrow of patients with multiple myeloma and the effect of peripheral blood admixture. Scr Med 2009;82:59-62.
21. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-85.
22. Pour L, Svachova H, Adam Z, et al. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 2009 Sep 26. [Epub ahead of print].
23. Němec P, Grešliková H, Smetana J, et al. Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy. Haematologica 2008;92:162a.
24. Sonneveld P, Hajek R, Nagler A, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/ lenalidomide therapy. Cancer 2008;112:1529-37.
25. Barlogie B, Tricot GJ, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006;135:158-64.
26. Attal M, Harousseau JL, Facon T, et al. InterGroupe Francophone du Myelome: single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502. Erratum in: N Engl J Med. 2004; 350(25):2628.
27. Maisnar V, Radocha J, Büchler T, et al. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. Eur J Haematol 2007;79:305- 9. Epub 2007 Sep 4.